Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

Neuromyelitis Optica Spectrum Disorder Clinical Trial

Official title:

NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01845584
• Other study ID #: NPB-01-08/E-01
• Status: Completed
• Phase: Phase 2
• First received: April 26, 2013
• Last updated: April 11, 2017
• Start date: May 2013
• Est. completion date: August 2015

Study information

• Verified date: April 2017
• Source: Nihon Pharmaceutical Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Patients diagnosed with anti-aquaporin 4 antibody positive Neuromyelitis Optica spectrum disorder were confirmed based on diagnostic criteria. Patients who meet all inclusion criteria and do not conflict with the exclusion criteria will receive steroid plus therapy （1g/day for five consecutive days）. Subsequently, patients who not provided adequate effect of therapy to steroids plus therapy will receive NPB-01 (intravenous immunoglobulin) 400mg/kg/day for five consecutive days. Patients evaluated Quantification of nerve and spinal cord impairment （QOSI） and the Expanded Disability Status Scale （EDSS）/ Functional Systems （FS） and anti-aquaporin 4 antibody et al.

As a safety endpoint, the safety of NPB-01 will be investigated the occurrence of adverse events by one year after the start of the study treatment.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Patients who become positive for anti-aquaporin 4 antibody or have becomed.

2. Patients who have developed myelitis.

3. Patients who run beyond greater than 30 days at least from last time in relapse.

4. Patients who new neurological symptom or worsening neurological symptom or flared neurological symptom have sustained 24 hours at least not associated fever or infection.

5. Patients who have an acute exacerbation at informed consent.

6. Patients who need steroid plus therapy(1g/day for five consecutive days).

7. Patients who can start steroid plus therapy within 3 days after informed consent.

8. Patients who be inadequate to effect to steroid plus therapy.

9. Patients with greater than or equal to twenty years old at informed consent.

Exclusion Criteria:

1. Patients who have developed optic neuritis.

2. Patients treated with intravenous immunoglobulin within 14 days before informed consent.

3. Patients with malignancy at informed consent.

4. Patients with history of shock or hypersensitivity for NPB-01.

5. Patients with IgA deficiency.

6. Patients with impaired liver function.

7. Patients with impaired renal function.

8. Patients with cerebro- or cardiovascular disorders.

9. Patients with high risk of thromboembolism.

10. Patients with hemolytic/hemorrhagic anemia.

11. Patients with decreased cardiac function.

12. Patients with decreased platelet.

Related Conditions & MeSH terms

• Disease
• Neuromyelitis Optica
• Neuromyelitis Optica Spectrum Disorder

Intervention

Drug:
• NPB-01

Locations

Country	Name	City	State
Japan	Japan	Osaka,

Sponsors (1)

Lead Sponsor	Collaborator
Nihon Pharmaceutical Co., Ltd

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline Quantification of nerve and spinal cord impairment (QOSI) at 29 days		29 days
Primary	Change from Baseline Expanded Disability Status Scale (EDSS)/ Functional Systems (FS) at 29 days		29 days
Primary	Change from Baseline anti-aquaporin 4 antibody at 29 days		29 days